<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1147">
  <stage>Registered</stage>
  <submitdate>6/03/2006</submitdate>
  <approvaldate>11/05/2006</approvaldate>
  <actrnumber>ACTRN12606000168550</actrnumber>
  <trial_identification>
    <studytitle>PreFER MVP For Elective Replacement</studytitle>
    <scientifictitle>PreFER MVP For Elective Replacement: Previously paced patients, coming in For Elective Replacement, using MVP (Managed Ventricular Pacing): to demonstrate the benefit of MVP in pacemaker and implantable carvioverter defibrillator (ICD) patients with a history of right ventricular pacing. The MVP function reduces unnecessary right ventricular pacing which has been shown to induce heart failure. Total mortality and heart failure hospitalization will be evaluated.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ClinicalTrials.gov: NCT00293241</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Patients with a history of RV pacing</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Replacement of pacemaker or ICD with a new device featuring MVP. Results after a follow-up period of 2 years with MVP "ON" vs MVP "OFF" will be compared. At the end of the 2 years the doctor will determine which settings are preferred for the patient to be left on.</interventions>
    <comparator>MVP "OFF"</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Demonstrate that MVP is superior to common clinical pacemaker and ICD programming in terms of freedom from all cause mortality or hospitalization for cardiovascular causes.</outcome>
      <timepoint>Measured at the end of 2 year follow-up period.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Occurence of Atrial Fibrillation/Atrial Tachycardia (AF/AT).</outcome>
      <timepoint>Timepoint measured: at the end of 2 year follow-up period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Compare Left Ventricular Ejection Flow</outcome>
      <timepoint>Timepoint measured: at the end of 2 year follow-up period.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patient with dual chamber pacemaker or ICD, paced for at least 2 years, who are due for a replacement of their device, male or female, who have signed the consent form or have a legal guardian willing to sign the consent form.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> Patient with cardiac resynchronization therapy indications, or permanent atrial fibrillation, or permanent atrioventricular block.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by internet</concealment>
    <sequence>Stratified by Ejection Fraction and pacemaker vs ICD. Randomization is performed centrally using Trial XS remote data entry system.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/04/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>801</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Medtronic Inc</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Medtronic Australiasia</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study protocol outlines the methodology and background behind the hypothesis that less ventricular pacing in a pacemaker and ICD is beneficial to the patients with a history of right ventricular pacing. This will be evaluated by comparing the rate of patient deaths and the need for hospitalizations when using less ventricular pacing vs. the normal, standard amount of ventricular pacing.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Henri Heynen</name>
      <address>Medtronic Australasia
667 High Street
Kew East VIC 3102</address>
      <phone>+61 3 88511007</phone>
      <fax />
      <email>henri.heynen@medtronic.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Henri Heynen</name>
      <address>Medtronic Australasia
667 High Street 
Kew East VIC 3102</address>
      <phone>+61 3 88511007</phone>
      <fax />
      <email>henri.heynen@medtronic.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>